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In the wake of the United Nations General Assembly 
Special Session on the World Drug Problem, which did 
not explicitly mention harm reduction in its outcome 
document,1 Louisa Degenhardt and colleagues 
highlight one aspect of the human cost of the global 
response for people who inject drugs in the public 
health context.2 The rise in disease burden of HIV, 
hepatitis B virus (HBV), and hepatitis C virus (HCV) 
attributed to injecting drug use between 1990 and 
2013 is reﬂ ective of the lack of success in supply 
and demand reduction approaches, combined with 
the struggle for legitimacy faced by harm reduction 
programmes and the fact that they remain unavailable 
in more than half of countries worldwide.3 The four-
times increase in disability-adjusted life-years, mainly 
due to increased mortality, results from a two-decade-
long inability to mount an eﬀ ective global public 
health response to injecting drug use and comorbid 
viral infections. Most mortality from these infections 
is due to transmission events that occurred 10–30 years 
previously. Mortality up to and including 2000 was 
largely unimpeded by treatment because of insuﬃ  cient 
treatment access in much of the world. However, if 
there is increased treatment availability for HIV, HBV, 
and HCV infections among people who inject drugs, 
mortality would begin to slow as has been seen in the 
past 5 years with the major scale-up of antiretroviral 
treatment for all people living with HIV.4 However, 
needle and syringe programmes (which started in the 
1970s) and medically assisted treatment with synthetic 
opioids (which started in the 1940s) have existed for 
decades before the current antiretroviral treatment era, 
but are still not widely available. 
The current reliance of the global response on 
attempts to reduce supply and demand ﬂ ies in 
the face of history. In the 19th century, the British 
waged war on China in defence of British and other 
merchants’ ability to sell opium in China without 
restriction.5 Today’s merchants of opium and other 
narcotics, who are mostly non-state actors, continue 
to ﬁ ght to sell their products. And just as with the 
Opium Wars, the merchants are not losing. Opium 
production continues largely unabated and new trade 
routes, possibly pushed by attempts to delay, disrupt, 
or destroy existing supply routes, spread into areas 
previously untouched by heroin, such as Kisumu in 
Kenya.6,7 Global numbers of people who inject drugs, 
as estimated by United Nations Oﬃ  ce on Drugs and 
Crime, WHO, and UNAIDS, have plateaued in recent 
years but data are not available from many countries 
with some evidence of heroin use.5 It is therefore 
crucial that eﬀ orts be refocused on evidence-based 
prevention and treatment programmes.
Degenhardt and colleagues’ calculations of the popu-
lation attributable fraction of injecting drug use for HIV, 
HBV, and HCV support the idea that a com pre hensive 
approach to prevention, including needle and syringe 
programmes and medically assisted treat ment, could 
achieve much to reduce virus transmission.8 In particular, 
the burden from hepatitis C could be substantially 
reduced by eﬀ ective prevention programmes. 
The indiﬀ erence of too many authorities to the plight 
of people who inject drugs ignores the burden injecting 
drug use places on families and communities, as well as 
on the individuals themselves. The recent government-
sanctioned killing of nearly 2000 people involved in 
drugs in the Philippines is just the latest and perhaps 
most vicious manifestation of violations of the human 
rights of drug users.9 The global community should 
consider Degenhardt and colleagues’ ﬁ ndings and 
seek new, more eﬀ ective approaches to the world 
drug problem.
Keith Sabin
UNAIDS, Geneva 1211, Switzerland 
sabink@unaids.org
I declare no competing interests. The views presented are those of the author and 
not necessarily his institution.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access 
article under the CC BY NC ND license
1 United Nations. Resolution adopted by the General Assembly on 19 April 
2016. S-30/1. Our joint commitment to eﬀ ectively addressing and 
countering the world drug problem. https://documents-dds-ny.un.org/
doc/UNDOC/GEN/N16/110/24/pdf/N1611024.pdf?OpenElement 
(accessed Aug 29, 2016).
2 Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of 
disease attributable to injecting drug use as a risk factor for HIV, hepatitis 
C, and hepatitis B: ﬁ ndings from the Global Burden of Disease Study 
2013. Lancet Infect Dis 2016; published online Sept 20. http://dx.doi.
org/10.1016/S1473-3099(16)30325-5
3 Harm Reduction International. Global State of Harm Reduction 2014. 
London: Harm Reduction International, 2014.
4 UNAIDS 2016. Global AIDS update 2016. Geneva: Joint United Nations 
Programme on HIV/AIDS, 2016.
5 Perdue PC. The ﬁ rst opium war: the Anglo-Chinese war of 1839–1842. 
http://ocw.mit.edu/ans7870/21f/21f.027/opium_wars_01/ow1_essay01.
html (accessed Aug 26, 2016).
























www.thelancet.com/infection   Vol 16   December 2016 1313
Eliminating hepatitis B virus as a global health threat
In The Lancet Infectious Diseases, Shevanthi Nayagam 
and colleagues1 report a modelling study on the 
eﬀ ectiveness of diﬀ erent interventions on the incidence 
and mortality rate of chronic hepatitis B virus (HBV) 
infec tion. To appreciate the implications of this 
report, we need to understand the context. Chronic 
viral hepatitis is the seventh leading cause of death 
worldwide.2 Chronic HBV infection alone aﬀ ects over 
240 million people worldwide and is one of the most 
common causes of cirrhosis and liver cancer.3 In May, 
2014, the World Health Assembly requested WHO 
to provide the necessary technical support to enable 
member states to develop robust national viral hepatitis 
prevention, diagnosis, and treatment strategies. In 
response, WHO set ambitious goals of reducing new 
cases of chronic viral hepatitis by 90%, and reducing 
mortality rates from these infections by 65% between 
2015 and 2030.4 Achievement of these goals might at 
least eliminate chronic viral hepatitis as a major global 
health threat. What can we do to make this happen?
Nayagam and colleagues1 ﬁ rst assessed the situation 
at present and compared it with a hypothetical situation 
where no intervention had previously been used to 
combat HBV.1 It is gratifying to note that current 
interventions have already had a huge impact: averting 
210 million new chronic HBV infections by 2015 and 
1·1 million deaths between 2015 and 2030. Nonetheless, 
63 million new cases and 17 million HBV-related deaths 
will still occur between 2015 and 2030. The authors then 
evaluated ﬁ ve strategies, including scaling-up infant 
vaccination coverage to 90%, birth-dose vaccination 
coverage to 80%, peripartum antivirals coverage for 
mothers with positive hepatitis B e antigen to 80%, 
increasing access to antivirals to 80%, and developing 
a cure for HBV infection. The ﬁ rst three interventions 
target new infections, whereas HBV treatments prevent 
disease progression, cirrhotic complications, and liver 
cancer.
Compared with the present state, scaling-up infant 
vaccination can prevent 4·3 million new infections 
from 2015 to 2030, but the real impact comes from 
birth-dose vaccination, which prevented 18·7 million 
new cases of HBV infection. The smaller eﬀ ect of infant 
vaccination compared with birth-dose vaccination 
is because infant vaccination is ineﬀ ective against 
mother-to-child transmission, which is the primary 
route of transmission in endemic areas. Even with 
vaccination or hepatitis B immunoglobulin at birth, 
women with very high viral loads might still transmit 
HBV to their children,5 and the use of antivirals during 
late pregnancy has been shown to almost eliminate 
mother-to-child transmission in this situation.6,7 In 
Nayagam and colleagues’ model,1 peripartum antivirals 
can further prevent 0·6 million new cases. Further 
studies are needed to deﬁ ne the long-term safety of 
peripartum antivirals in mothers and children. Based 
on these data, low-income countries should prioritise 
birth-dose vaccination over peripartum antivirals if they 
do not have the resources to implement both strategies 
at the same time because the birth-dose vaccination will 
have a bigger impact than peripartum antivirals.
Because most cases of cirrhosis and liver cancer 
occur during or after middle age, prevention of new 
infections will not have a major eﬀ ect on HBV-related 
mortality rates until decades later. Management of 
patients who have already been infected is, therefore, 
important. Although only one placebo-controlled trial 
has used clinical outcomes as the primary endpoint,8 
several observational studies suggest that antivirals 
can reduce the risk of liver cancer and mortality.9 The 
main drawback of antiviral therapy is that long-term 
treatment is often needed, but drug resistance and 
side eﬀ ects are rare with entecavir or tenofovir, which 
makes long-term treatment acceptable.10 Based on 
the estimations in Nayagam and colleagues’ study, 
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